This confirmation expands upon the FDA's previous No Objection Letters for Nascent's Reb A to now include all steviol glycosides extracted from the leaf.
Wommack, who currently serves as CRN’s senior vice president, will follow the foundation’s plan to prioritize access to nutritional products and education.